<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress.com" -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd"
	xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
	xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
	xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
	>
<url><loc>https://trainedmarketmonkey.com/2026/05/01/the-little-robot-that-could-but-probably-wont-at-least-not-yet/</loc><news:news><news:publication><news:name>Trained Market Monkey</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-05-01T15:51:42+00:00</news:publication_date><news:title>The Little Robot That Could (But Probably Won&#8217;t, At Least Not Yet)</news:title><news:keywords>technical analysis, momentum stocks, growth investing, monkey momentum index, venture capital, emerging tech, investment thesis, market opportunity, revenue growth, interest rates, Beta, risk management, Food Delivery, Profitability, competitive moat, cash burn, momentum investing, Serve Robotics, robotics stocks, autonomous delivery, last-mile delivery, small-cap stocks, unit economics, Analyst ratings, market sentiment, debt-to-equity, short squeeze, regulatory risk, earnings forecast, automation, SPAC, Q1 earnings, industrial robots, burn rate, San Francisco robotics, AI companies</news:keywords></news:news></url><url><loc>https://trainedmarketmonkey.com/2026/05/01/the-protein-disposal-business-is-booming-but-this-stock-is-burning-cash-like-a-monkey-on-fire/</loc><news:news><news:publication><news:name>Trained Market Monkey</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-05-01T14:52:39+00:00</news:publication_date><news:title>The Protein Disposal Business Is Booming (But This Stock Is Burning Cash Like a Monkey on Fire)</news:title><news:keywords>interest rate risk, sector rotation, monkey momentum index, Biotech, cash burn, clinical trials, medical innovation, biotech investing, emerging biotech, debt-to-equity, Phase 2, Phase 1, drug development, healthcare stocks, pipeline risk, biotech valuation, speculative biotech, small-cap biotech, FDA approval pathway, ARVN, Arvinas, PROTAC, proteolysis targeting, vepdegestrant, breast cancer, Parkinson&#039;s disease, ARV-102, NDA filing, protein degradation, Pfizer partnership, Roche collaboration, negative revenue growth, clinical stage company, 2026 catalysts, high-risk stocks, oncology, neurology, market cap under 1B</news:keywords></news:news></url><url><loc>https://trainedmarketmonkey.com/2026/04/30/the-casino-landlord-who-never-gambles-but-you-might-want-to/</loc><news:news><news:publication><news:name>Trained Market Monkey</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-30T21:10:27+00:00</news:publication_date><news:title>The Casino Landlord Who Never Gambles (But You Might Want To)</news:title><news:keywords>VICI, dividend stocks, dividend growth, income investing, valuation analysis, real estate investment trust, interest rate sensitivity, income generation, portfolio diversification, VICI Properties, Caesars Palace, MGM Grand, experiential real estate, gaming properties, debt to equity, leverage risk, Recession resistant, 6% yield, stable cash flow, Venetian Resort, Las Vegas, hospitality REIT, triple-net lease, low volatility stocks, medium-term investing, consumer spending, casino stocks, safe dividends, capital gains, FFO, adjusted funds from operations, property ownership, operator risk, commercial real estate, mortgage REIT alternative, entertainment real estate, travel stocks</news:keywords></news:news></url><url><loc>https://trainedmarketmonkey.com/2026/04/30/the-chip-giants-expensive-nap-and-why-it-might-not-wake-up/</loc><news:news><news:publication><news:name>Trained Market Monkey</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-30T21:07:57+00:00</news:publication_date><news:title>The Chip Giant&#8217;s Expensive Nap (And Why It Might Not Wake Up)</news:title><news:keywords>technical analysis, earnings growth, sector rotation, blue chip stocks, interest rates, risk management, Profitability, Free Cash Flow, forward PE ratio, momentum investing, investor psychology, market sentiment, financial engineering, debt-to-equity, unprofitable companies, value trap, market corrections, beta risk, cash flow negative, macro headwinds, portfolio risk, position sizing, balance sheet analysis, sell signal, Intel, INTC, Semiconductors, turnaround risk, AI bubble, chip industry, TSMC, AMD, ASML, foundry business, growth vs value, narrative investing</news:keywords></news:news></url><url><loc>https://trainedmarketmonkey.com/2026/04/29/the-midstream-monkeys-dilemma-when-5-7-looks-too-good-to-be-true/</loc><news:news><news:publication><news:name>Trained Market Monkey</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-29T20:21:48+00:00</news:publication_date><news:title>The Midstream Monkey&#8217;s Dilemma: When 5.7% Looks Too Good to Be True</news:title><news:keywords>dividend sustainability, utility stocks, dividend stocks, income investing, payout ratio, monkey momentum index, energy transition, investment thesis, interest rates, high yield, earnings analysis, EPD, Enterprise Products Partners, Energy Infrastructure, pipeline stocks, natural gas, crude oil pipelines, petrochemicals, geopolitical risk, leverage, midstream energy, oil and gas, market sentiment, financial commentary, margin of safety, recession risk, Portfolio allocation, MLP, capital structure, PEG ratio, distribution yield, long-term income, 52-week high, ESG pressure, LNG exports, Strait of Hormuz, fee-based business model</news:keywords></news:news></url></urlset>
